Subject(s)
COVID-19/virology , Hyperesthesia/virology , SARS-CoV-2/pathogenicity , Skin Diseases, Viral/virology , Adult , Analgesics/therapeutic use , COVID-19/complications , COVID-19/diagnosis , Female , Host-Pathogen Interactions , Humans , Hyperesthesia/diagnosis , Hyperesthesia/drug therapy , Male , Middle Aged , Skin Diseases, Viral/diagnosis , Skin Diseases, Viral/drug therapy , COVID-19 Drug TreatmentABSTRACT
A 50-year-old man presented to our dermatology clinic with itchy skin rash. The rash began 5 days after systemic symptoms appeared such as mild fever and mild dyspnoea. The rashes were a characteristic of follicular eruption, which started on his stomach and spread all over his body. After a thorough evaluation, he was diagnosed with COVID-19 and was started on COVID-19 regimens. Skin lesions disappeared on the ninth day of treatment. Our findings contribute to the growing awareness of dermatological manifestations in patients with COVID-19.
Subject(s)
Coronavirus Infections/diagnosis , Exanthema/diagnosis , Pneumonia, Viral/diagnosis , Skin Diseases, Viral/diagnosis , Anti-Bacterial Agents/therapeutic use , Antiviral Agents/therapeutic use , COVID-19 , Coronavirus Infections/drug therapy , Diagnosis, Differential , Drug Therapy, Combination , Dyspnea/diagnosis , Dyspnea/etiology , Exanthema/drug therapy , Fever/diagnosis , Fever/etiology , Humans , Male , Middle Aged , Pandemics , Pneumonia, Viral/drug therapy , Skin Diseases, Viral/drug therapy , Treatment OutcomeSubject(s)
COVID-19/virology , SARS-CoV-2/pathogenicity , Skin Diseases, Viral/virology , Skin/virology , Antiviral Agents/therapeutic use , COVID-19/complications , COVID-19/diagnosis , Female , Glucocorticoids/therapeutic use , Host-Pathogen Interactions , Humans , Middle Aged , SARS-CoV-2/drug effects , Skin/drug effects , Skin/pathology , Skin Diseases, Viral/diagnosis , Skin Diseases, Viral/drug therapy , Treatment Outcome , COVID-19 Drug TreatmentABSTRACT
In the beginning of the COVID-19 outbreak, skin manifestations, if present, were not paid enough attention. Then, the focus moved toward the impact of the prolonged use of personal protective measures in both healthcare workers and patients. In the meantime, attention is increasingly paid to dermatology as a result of the concern for certain groups of dermatologic patients, including those whose condition may worsen by the thorough disinfection measures and those treated with immunosuppressants or immunomodulators. Following patients with psoriasis on biological therapy, as well as other inflammatory and autoimmune cutaneous disorders such as atopic dermatitis, pemphigus, pemphigoid diseases, and skin cancer provoked the interest of dermatologists. Finally, an intriguing question to the dermatologic society was whether skin changes during COVID-19 infection exist and what could be their diagnostic or prognostic value. Here, we summarize skin conditions during the COVID-19 pandemic, patient information, and expert recommendations and give an overview about the registries launched to document skin changes during COVID-19, as well as details about certain patient groups infected with SARS-CoV-2, for example, psoriasis, atopic dermatitis, and autoimmune bullous diseases.
Subject(s)
COVID-19/complications , Skin Diseases, Viral/virology , Chilblains/virology , Erythema/virology , Exanthema/virology , Humans , Livedo Reticularis , Patient Education as Topic , Purpura/virology , Registries , SARS-CoV-2 , Skin Diseases, Vesiculobullous/virology , Skin Diseases, Viral/drug therapy , Skin Diseases, Viral/etiology , Urticaria/virologySubject(s)
Antiviral Agents/adverse effects , Betacoronavirus , Coronavirus Infections/complications , Drug Eruptions/etiology , Hydroxychloroquine/adverse effects , Lopinavir/adverse effects , Pneumonia, Viral/complications , Ritonavir/adverse effects , Skin Diseases, Viral/etiology , Anti-Inflammatory Agents/therapeutic use , Antiviral Agents/therapeutic use , Benzimidazoles/therapeutic use , Betamethasone/analogs & derivatives , Betamethasone/therapeutic use , COVID-19 , Causality , Coronavirus Infections/drug therapy , Drug Eruptions/drug therapy , Drug Therapy, Combination , Humans , Hydroxychloroquine/therapeutic use , Lopinavir/therapeutic use , Male , Middle Aged , Pandemics , Piperidines/therapeutic use , Pneumonia, Viral/drug therapy , Prednisone/therapeutic use , Ritonavir/therapeutic use , SARS-CoV-2 , Skin Diseases, Viral/drug therapyABSTRACT
COVID-19 had a great impact on medical approaches among dermatologist. This systematic review focuses on all skin problems related to COVID-19, including primary and secondary COVID-related cutaneous presentations and the experts recommendations about dermatological managements especially immunomodulators usage issues. Search was performed on PubMed, Scopus, Embase and ScienceDirect. Other additional resources were searched included Cochrane, WHO, Medscape and coronavirus dermatology resource of Nottingham university. The search completed on May 3, 2020. Three hundred seventy-seven articles assigned to the inclusion and exclusion groups. Eighty-nine articles entered the review. Primary mucocutaneous and appendageal presentations could be the initial or evolving signs of COVID-19. It could be manifest most commonly as a maculopapular exanthamatous or morbiliform eruption, generalized urticaria or pseudo chilblains recognized as "COVID toes" (pernio-like acral lesions or vasculopathic rashes). During pandemic, Non-infected non-at risk patients with immune-medicated dermatologic disorders under treatment with immunosuppressive immunomodulators do not need to alter their regimen or discontinue their therapies. At-risk o suspected patients may need dose reduction, interval increase or temporary drug discontinuation (at least 2 weeks). Patients with an active COVID-19 infection should hold the biologic or non-biologic immunosuppressives until the complete recovery occur (at least 4 weeks).
Subject(s)
COVID-19/complications , Immunosuppressive Agents/administration & dosage , Skin Diseases, Viral/etiology , Chilblains/virology , Humans , Immunosuppressive Agents/adverse effects , Skin Diseases/drug therapy , Skin Diseases/immunology , Skin Diseases, Viral/drug therapy , Skin Diseases, Viral/physiopathologySubject(s)
Anti-Inflammatory Agents/therapeutic use , COVID-19 Drug Treatment , Colchicine/therapeutic use , Exanthema/drug therapy , Pericarditis/drug therapy , Skin Diseases, Viral/drug therapy , COVID-19/complications , COVID-19/diagnosis , COVID-19/virology , Exanthema/diagnosis , Exanthema/virology , Female , Humans , Pericarditis/diagnosis , Pericarditis/virology , Skin Diseases, Viral/diagnosis , Skin Diseases, Viral/virology , Treatment Outcome , Young AdultABSTRACT
We report the case of a positive COVID-19 patient who presented to our hospital for a maculopapular skin rash which appeared 7 days after the onset of COVID-19 symptoms. He was 34 years old and nothing relevant was recorded at his previous anamnesis. The patient was hospitalized for 3 days and received systemic therapy with steroid, antihistamines, tocilizumab, and hydroxicloroquine. On the third day of the hospitalization the cutaneous rash had almost completely disappeared.